NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Iolyx Therapeutics

Iolyx Therapeutics

Private
Burlingame, CaliforniaHealthcare & Life Scienceshttps://iolyx.com/

Last Round

Series B

Dec 3, 2025

Total Funding Raised

$45M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Iolyx Therapeutics is a biotechnology company that develops targeted immunomodulatory therapies for ocular inflammatory and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

biopharmaceuticalophthalmic therapeuticsdry eye diseasedrug developmentautoimmune diseaseclinical-stage biotechbiotechdrug licensingimmunomodulatorophthalmologypharma partnershipR&Dbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Iolyx Therapeutics Comparables

Compare Iolyx Therapeutics with similar companies based on industry and business-model similarity.

Iolyx Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Stuart Therapeutics, Inc.
87%
TearSolutions
87%
Selagine, Inc.
83%

Iolyx Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BDec 3, 2025
Series AApr 20, 2023

Iolyx Therapeutics Investors

Notable investors and investment history

Iolyx Therapeutics investors
InvestorRounds
Frazier Healthcare PartnersSeries A
Frazier Life SciencesSeries B
CooleySeries B
Alumni VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 3, 2025

    $15M round completed.

  • Dec 3, 2025

    Partnering with Laboratoires Théa for autoimmune dry eye treatment.

Iolyx Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Iolyx Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Iolyx Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBurlingame, California
Employee Range10
Year Founded2019
Last FundingDec 3, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.